tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
TScan Therapeutics: Promising Developments and Strategic Advancements Drive Buy Rating
PremiumRatingsTScan Therapeutics: Promising Developments and Strategic Advancements Drive Buy Rating
2M ago
Strategic Advancements and Promising Trial Data Propel TScan Therapeutics to ‘Buy’ Rating
Premium
Ratings
Strategic Advancements and Promising Trial Data Propel TScan Therapeutics to ‘Buy’ Rating
2M ago
TScan Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
TScan Therapeutics Reports Q2 2025 Financial Results
3M ago
TScan Therapeutics management to meet virtually with BTIG
PremiumThe FlyTScan Therapeutics management to meet virtually with BTIG
6M ago
TScan Therapeutics price target lowered to $10 from $15 at H.C. Wainwright
Premium
The Fly
TScan Therapeutics price target lowered to $10 from $15 at H.C. Wainwright
6M ago
TScan Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
TScan Therapeutics Reports Q1 2025 Financial Results
6M ago
TScan Therapeutics: Promising Advances in TCR-Engineered Cancer Therapies Justify Buy Rating
PremiumRatingsTScan Therapeutics: Promising Advances in TCR-Engineered Cancer Therapies Justify Buy Rating
8M ago
Positive Buy Rating for TScan Therapeutics Driven by Promising Clinical Data and Strong Financial Position
Premium
Ratings
Positive Buy Rating for TScan Therapeutics Driven by Promising Clinical Data and Strong Financial Position
8M ago
TScan Therapeutics price target lowered to $3 from $14 at Barclays
Premium
The Fly
TScan Therapeutics price target lowered to $3 from $14 at Barclays
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100